|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)статья
Статья опубликована в высокорейтинговом журнале
Информация о цитировании статьи получена из
Web of Science
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 6 декабря 2018 г.
- Авторы: Chowdhury S., Birtle A.J., Bjartell A., Costa L.A., Feyerabend S., Galli L., Kalinka-Warzocha E., Kramer G., Maroto Rey J.P., Lumen N., Matveev V.B., Paiss T., Spaeth D., Antoni L., Klumper E., Wapenaar R., Lee E.
- Журнал: Annals of Oncology
- Том: 27
- Номер: 6
- Год издания: 2016
- Издательство: Oxford University Press
- Местоположение издательства: United Kingdom
- Первая страница: 746P
- Последняя страница: 746
- DOI: 10.1093/annonc/mdw372.30
- Аннотация: Background: The Prostate Cancer Registry (NCT02236637) is the first prospective, international, observational study to describe routine management of mCRPC. The registry has enrolled over 3000 patients, with up to 3 years' follow-up. This analysis reports baseline characteristics, treatments and first clinical outcomes in 1374 patients. Methods: Data collected prospectively from medical records of men with documented mCRPC initiating a new mCRPC treatment or in surveillance (no active treatment; ongoing androgen deprivation and/or bone-targeted therapy allowed). Data and analyses were descriptive. Results: Median follow-up at database close was 14.2 months (range: 0.2-28.6). Mean age at enrolment was 72.6 years; 55% of patients had a Gleason score ≥ 8 at diagnosis. 58.5% of patients had comorbidities at enrolment, most commonly cardiovascular disorders (51.7%; 41.3% hypertension) and diabetes (15.2%). 876 patients (63.8%) were chemotherapy-naïve at enrolment. During the 12-month observation period, 1191 patients (86.7%) initiated new mCRPC treatment. Descriptive, non-comparative data on previous treatment lines and time to next therapy by first documented treatment received on study are in the table. Chemotherapy-naïve treatment Chemotherapy-naïve treatment First chemotherapy treatment Post-chemotherapy treatment Post-chemotherapy treatment Post-chemotherapy treatment Post-chemotherapy treatment First documented treatment received on study (treatments with n ≥ 50) Abiraterone acetate + prednisone (n = 324) Enzalutamide (n = 53) Docetaxel (n = 326) Abiraterone acetate + prednisone (n = 164) Enzalutamide (n = 111) Docetaxel (n = 58)` Cabazitaxel (n = 119) Number of previous mCRPC treatments, n (%) 0 313 (96.6) 42 (79.2) 295 (90.5) 0 0 0 0 1 11 (3.4) 11 (20.8) 29 (8.9) 121 (73.8) 61 (55.0) 35 (60.3) 43 (36.1) 2 0 0 2 (0.6) 37 (22.6) 29 (26.1) 14 (24.1) 59 (49.6) ≥3 0 0 0 6 (3.6) 21 (18.9) 9 (15.5) 17 (14.3) Median time to next therapy, days (95% CI)* 601 (467, NE) 503 (251, NE) 278 (259, 307) 428 (359, 514) 366 (296, NE) 322 (239, 404) 264 (240, 321) *Kaplan–Meier estimates; patients with no next therapy were censored. Time to next therapy: time from start of 1st therapy to start of next therapy. NE, not estimable. Conclusions: The results provide unique insights into treatment and outcomes in a large, real-world mCRPC patient population. These older patients have a high prevalence of comorbidities that are common in clinical practice but often not taken into account in the results of interventional clinical trials. Follow-up of these patients will allow assessment of treatment patterns and outcomes, and thereby contribute to optimising outcomes in subsets of mCRPC patients in clinical practice. Clinical trial identification: ClinicalTrials.gov NCT02236637
- Добавил в систему: Матвеев Всеволод Борисович